World Hematology 2020

Join us at Edinburgh, UK this March 2-3, 2020 to explore trends in hematology and oncology. For more info, PS: https://rebrand.ly/39g47

World Hematology 2020

Join us at Edinburgh, Scotland this March to explore hematology & oncology with experts in the field. We offer 25% discount on group registrations. Grab your slots now. Know more at: https://rebrand.ly/39g47

World Hematology 2020

Edinburgh, UK is all set for World Hematology 2020. Join us at the venue, this March 2-3, 2020 to discuss the trends in the field of hematology and oncology and enjoy the climate exploring multicultural special events. For more info, PS: https://rebrand.ly/39g47

Updates in hematology/ oncology

Studies say that anemia is an early and multifactorial complication of multiple myeloma and has been reported to occur in over two thirds of all patients. It also has a negative impact on the quality of patients’ lives and is an independent predictor of poor survival. It is also said that in patients with multiple myeloma, anaemia is usually normocytic and normochromic but can be macrocytic and the anaemia is manifested as a hemoglobin level between 8 and 10 g/dL, while approximately 10% have a value below 8 g/dL. Serum iron levels are usually normal to mildly low; serum ferritin is high and hemosiderin is significant in bone marrow macrophages, consistent with patterns similar to anemia of chronic disease. It is also said that chemotherapy-responsive patients, with or without exogenous erythropoietin administration, often see a normalization of their haemoglobin levels with a resultant improvement in quality of life, despite the impact of patients’ ages and stages of disease.

To discuss more such interesting findings in hematology and oncology, join us at the best hematology, oncology, cancer, leukemia, lymphoma and blood conferences organized. To know more info, PS: Hematology & Oncology congress

 

World Hematology 2020

Scan the code and get the information to join us at the leading and one of the best hematology and oncology conferences held in UK.  PS: https://hematology.cmesociety.com/

Happy New Year 2020

Let's begin the 1st year of 2020s with good health, peace and prosperity. World Hematology 2020 wishes all a very happy new year.
#NewYear #NewYear2020 #Blood #hematology #Cancer #oncology #SickleCell #anemia #CancerResearch #breastcancer #conferences #event #meetandgreet #cancerconferences #oncologyconferences #lymphoma #leukemia #hematologyconferences #happynewyear #myeloma #prosperity #year #wishes #bloodconferences

World Hematology 2020

Join us at the largest and leading hematology & oncology congress, early this new year and explore great things with experts in the field. Come, greet and meet experts this March 2-3, 2020 in Edinburgh, Scotland. More info: https://hematology.cmesociety.com/

#hematology #blood #cancer #oncology #leukemia #lymphoma #anemia #bloodcancer #hematologyconferences #hematologyoncology 

Updates in hematology/ oncology

Do you know the most frequent clinical manifestation in multiple myeloma?

The answer to this question goes this way.......

The clinical manifestations in multiple myeloma generally be

• Anemia: 73%
• Osteolytic bone lesions: 67%
• Bone pain: 58%
• Kidney Failure: 48%
• Hypercalcemia: 28%

So, the most frequent manifestation in multiple myeloma is anemia.

To know more interesting updates in hematology and oncology, join us at, PS: World Hematology 2020

World Hematology 2020

We have our speaker slots open. Submit your abstracts now and avail early bird offers on registration. We offer special group registration benefits. To know more, PS: https://hematology.cmesociety.com/

World Hematology 2020

Come and Join us in Scotland to witness the gathering of experts in hematology & oncology, this March 2- 3, 2020. More info, PS: https://hematology.cmesociety.com/

#hematology #leukemia #lymphoma #cancer #oncology #Conference #events #meetings #Congress #conferences #AML #Blood #anemia #MDS

World Hematology 2020

Join us at the leading and largest conference on hematology & oncology in Edinburgh, Scotland, this March 2020. Submit your abstracts now & avail early bird offers in registration! For more info, PS: https://hematology.cmesociety.com/abstract-submission

Recent updates in hematology & oncology

Trials show, azacitidine & pembrolizumab combination is safe, feasible and well-tolerated for relapsed and refractory AML. Explore more trends in hematology & oncology at: https://hematology.cmesociety.com 

Recent updates in hematology/ oncology

FDA has approved acalabrutinib for adults with chroniclymphocytic leukemia or small lymphocytic lymphoma as an initial or subsequent therapy. This would mark the second approval under Project Orbis.

FDA used the Real-Time Oncology Review pilot program in its review of the application for acalabrutinib, a process to streamline the submission of data before the completion of the entire drug application “Today, as part of a U.S., Australian and Canadian collaboration known as Project Orbis, the U.S. approved a new treatment option for those living with chronic lymphocytic leukemia or small lymphocytic lymphoma. The FDA’s Project Orbis provides a framework for concurrent submission and review of oncology drug applications among the FDA’s international partners,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, said in a press release.

The FDA based this supplemental approval of acalabrutinib on data from two randomized studies. 

The first trial, which included 535 patients with previously untreated CLL- showed longer PFS among patients assigned acalabrutinib compared with other standard treatments.

The second trial of 310 patients with CLL also showed longer PFS with acalabrutinib vs. other standard treatments.

Common adverse events associated with acalabrutinib included anemia, neutropenia, upper respiratory tract infection, thrombocytopenia headache, diarrhea and musculoskeletal pain.

For more updates on hematology or cancer, please join us at, PS: http://tiny.cc/9t8ybz

Source: Healio hemonc today

World Hematology 2020

FDA grants duvelisib orphan drug designation for the treatment of T-cell lymphoma. Know more oncology at: https://hematology.cmesociety.com/

World Hematology 2020

According to study, four months of induction combination chemotherapy followed by surgical exploration made secondary resection feasible for patients with nonresectable locally advanced pancreatic cancer. Know more oncology at: https://hematology.cmesociety.com/ 

 

Orphan drug status to CT053- Multiple myeloma

The FDA has given orphan drug status to CT053, an investigational chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma.

CT053 (CARsgen Therapeutics) is an autologous, fully human CAR T-cell therapy that targets the B-cell maturation antigen on the surface of cancer cells.

CARsgen’s CT053 is one of the company’s three CAR T-cell products approved for early-stage clinical trials. The others include humanized CD19 CAR-T for B-cell leukemia and lymphoma and GPC3 CAR-T for hepatocellular carcinoma and non-small cell lung cancer.

“FDA orphan designation is an important regulatory milestone in the continued development and commercialization of CT053 anti-BCMA CAR-T cells,” Zonghai Li, MD, PhD, founder, CEO and chief scientific officer of CARsgen said in a press release.

Li added that CT053 showed “outstanding potency” during an exploratory phase 1 clinical study in China, where 19 of 24 patients with relapsed or refractory multiple myeloma had a complete response to therapy. In addition, there were no cases of high-grade (3 or 4) cytokine release syndrome during the study.

The FDA Office of Orphan Products Development grants orphan drug designation to novel drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States. The designation allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials and — upon regulatory approval — 7 years of market exclusivity.

Source: https://www.healio.com/hematology-oncology/myeloma/news/online/%7B05b99e87-898a-4880-8a95-d4b724753854%7D/fda-grants-orphan-drug-status-to-anti-bcma-car-t-cell-therapy-for-multiple-myeloma

Recent Trends in Hematology & Oncology

Trials show that adding pembrolizumab to standard therapy failed to improve clinical outcomes for untreated or relapsed/refractory multiple myeloma. Explore more hemato-oncology at: http://bit.ly/2xaW3zT

Recent Trends in Hematology & Oncology

Trials show that nivolumab in combination with brentuximab vedotin induced high antitumor activity for relapsed or refractory primary mediastinal B-cell lymphoma. Explore more hemonc at: http://bit.ly/2xaW3zT

Recent Trends in Hematology/ Oncology

Research shows that combination of selinexor and dexamethasone induced responses among patients with refractory multiple myeloma. Explore more hemonc at: http://bit.ly/2xaW3zT

   

Recent Trends in Hematology/ Oncology

Research shows that combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells shows activity for relapsed or refractory multiple myeloma. Explore more hemonc at: http://bit.ly/2xaW3zT